Regulus Announces Continuation of RG-101 Clinical Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- US stocks on course for lower open as AI jitters hit Nvidia, chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Oil prices continue surge, rising 3% as attacks halt Saudi pipeline
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street's new pair trade: Long software, short chips
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Regulus Therapeutics (RGLS) PT Lowered to $8 at Wedbush; Clinical Hold Could Be Lifted in Q1 2018 at the Earliest
January 30, 2017 12:22 PM ESTWedbush lowered its price target on Regulus Therapeutics (NASDAQ: RGLS) to $8.00 (from $13.00) while maintaining a Outperform rating after the FDA requested additional safety data from preclinical experiments and an ongoing trial extends the RG-101 / HCV clinical hold into Q1 2018
Liana Moussatos commented. "... we now anticipate the clinical... More
Needham & Company Downgrades Regulus Therapeutics (RGLS) to Hold
January 30, 2017 7:28 AM ESTNeedham & Company downgraded Regulus Therapeutics (NASDAQ: RGLS) from Buy to Hold.
Analyst Alan Carr commented, "RGLS announced late Friday that FDA has extended RG-101 clinical hold and requested additional long-term clinical data from ongoing trials. These data are not expected until 4Q17.... More
Wells Fargo Downgrades Regulus Therapeutics (RGLS) to Market Perform
January 30, 2017 6:32 AM ESTWells Fargo downgraded Regulus Therapeutics (NASDAQ: RGLS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $2.25 yesterday.
... MoreRegulus Therapeutics (RGLS) PT Lowered to $2 at BMO Capital; Probability of RG-101 Success Down to 25%
January 30, 2017 5:58 AM ESTBMO Capital lowered its price target on Regulus Therapeutics (NASDAQ: RGLS) to $2.00 (from $5.00) while maintaining a Market Perform rating after the FDA has extended RG-101's clinical hold.
Analyst Matthew Luchini commented, "Our probability of success declines to 25% from 40%, reflecting increased clinical... More
Regulus Therapeutics (RGLS) Shares to Resume Trading at 4:40 PM ET
January 27, 2017 4:18 PM ESTRegulus Therapeutics (NASDAQ: RGLS) Shares to Resume Trading at 4:40 PM ET
... More